检索结果-南通市图书馆

International Journal of Ophthalmology(English edition) 2024年第6期17卷 1073-1078页

作者： Chu-Yuan Lou Yong Wang Jia-Yuan Xing Teng Ma Lei Tao Xiao-Tang Wang Run-Sheng Wang Neuroophthalmic Center Xi’an People’s Hospital(Xi’an Fourth Hospital)Xi’an 710004Shaanxi ProvinceChina

AIM:To investigate the short-term efficacy and safety of inebilizumab for neuromyelitis optica spectrum disorders(NMOSD).METHODS:A total of 33 patients with NMOSD treated with inebilizumab(Group INB,n=15)or rituximab(Group RTX,n=18)in addition to high-dose glucocorticoids were included.Both groups underwent hormone shock therapy during the acute phase.Subsequently,Group INB received inebilizumab injections during the remission phase,while Group RTX received rituximab injections.A comparison of aquaporins 4(AQP4)titer values,peripheral blood B lymphocyte counts,and visual function recovery was conducted before and 8wk after treatment.Additionally,adverse reactions and patient tolerability were analyzed after using inebilizumab treatment regimes.RESULTS:Following inebilizumab treatment,there was a significantly improvement in the visual acuity of NMOSD patients(Prituximab,which has previously demonstrated substantial therapeutic efficacy(P>0.05).Furthermore,inebilizumab exhibited higher safety levels than that of rituximab injections.CONCLUSION:The combination of inebilizumab and high-dose glucocorticoids proves to be effective.In comparison to rituximab injections,inebilizumab displays better tolerance and safety.Moreover,it demonstrates a partial effect in preventing optic nerve atrophy.Thus,it stands as an effective method to reduce the disability rates and improve the daily living ability of patients with NMOSD.

关键词： neuromyelitis optica spectrum disorders inebilizumab rituximab glucocorticoids

Bendamustine and rituximab as frontline therapy in extranodal marginal zone lymphoma:a single-institution experience

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Oncology Research 2024年第6期32卷 1031-1036页

作者： CONSTANTINE N.LOGOTHETIS NATHAN P.HORVAT TONY KURIAN CELESTE BELLO JULIO CHAVEZ LEIDY ISENALUMHE BIJAL SHAH LUBOMIR SOKOL HAYDER SAEED JAVIER PINILLA SAMEH GABALLA Department of Internal Medicine University of South FloridaTampaFL33602USA College of Medicine University of South Florida MorsaniTampaFL33602USA H.Lee Moffitt Cancer Center and Research Institute TampaFL33612USA

Extranodal marginal zone lymphoma(EMZL)encompasses 70%of cases of marginal zone lymphoma.Frontline bendamustine and rituximab(BR)were derived from trials involving other indolent non-Hodgkin’s lymphomas.Only one trial has evaluated frontline BR prospectively in EMZL.This retrospective study reports outcomes among EMZL patients receiving frontline BR.Twenty-five patients were included with a median age of 69 years(40–81).Five(20.0%)patients had stage Ⅰ/Ⅱ disease,and 20(80.0%)had stage Ⅲ/Ⅳ disease.The median number of cycles was 6.0(3.0–6.0).Maintenance rituximab was administered to 10(41.7%)individuals.Overall response rate(ORR)was 100.0%(60.0%complete response,40.0%partial response).Medians of overall survival and progression-free survival were not reached.The estimated 2-year progression-free survival was 85.2%and overall survival was 100.0%.Four(16.6%)patients had infections related to treatment;3(12.0%)transformed to diffuse large B-cell lymphoma;5(20.8%)had a relapse or progression of EMZL;and 3(12.0%)died unrelated to BR.BR is an efficacious and well-tolerated front-line regimen for EMZL with response data consistent with existing literature.

关键词： Extranodal marginal zone lymphoma Bendamustine rituximab Front-line therapy

BCD020 rituximab bioanalog compared to standard treatment in juvenile systemic lupus erythematosus: The data of 12 months casecontrol study

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Pediatrics 2024年第1期13卷 52-61页

作者： Elvira Kalashnikova Eugenia Isupova Ekaterina Gaidar Lyubov Sorokina Maria Kaneva Vera Masalova Margarita Dubko Tatiana Kornishina Natalia Lubimova Ekaterina Kuchinskaya Irina Chikova Rinat Raupov Olga Kalashnikova Mikhail Kostik Hospital Pediatry Department Saint-Petersburg State Pediatric Medical UniversitySaint-Petersburg 194100Russia Research Laboratory of Autoimmune and Autoinflammatory Diseases Almazov National Medical Research CentreSaint Petersburg 197341Russia Department of Rheumatology Turner National Medical Research Center forСhildren’s Orthopedics and Trauma SurgerySaint-Petetrsburg 197136Russia

BACKGROUND Systemic lupus erythematosus(SLE)is the most frequent and serious systemic connective tissue disease.Nowadays there is no clear guidance on its treatment in childhood.There are a lot of negative effects of standard-of-care treatment(SOCT),including steroid toxicity.rituximab(RTX)is the biological B-lymphocyte-depleting agent suggested as a basic therapy in pediatric SLE.AIM To compare the benefits of RTX above SOCT.METHODS The data from case histories of 79 children from the Saint-Petersburg State Pediatric Medical University from 2012 to 2022 years,were analyzed.The diagnosis of SLE was established with SLICC criteria.We compared the outcomes of treatment of SLE in children treated with and without RTX.Laboratory data,doses of glucocorticosteroids,disease activity measured with SELENA-SLEDAI,RESULTS Patients,treated with RTX initially had a higher degree of disease activity with prevalence of central nervous system and kidney involvement,compared to patients with SOCT.One year later the disease characteristics became similar between groups with a more marked reduction of disease activity(SELENA-SLEDAI activity index)in the children who received RTX[-19 points(17;23)since baseline]compared to children with SOCT[-10(5;15.5)points since baseline,P=0.001],the number of patients with active lupus nephritis,and daily proteinuria.During RTX therapy,infectious diseases had three patients;one patient developed a bi-cytopenia.CONCLUSION RTX can be considered as the option in the treatment of severe forms of SLE,due to its ability to arrest disease activity compared to SOCT.

关键词： Systemic lupus erythematosus Children rituximab Anti-B-cell therapy Glucocorticosteroids

rituximab as a treatment for human immunodeficiency virusassociated nemaline myopathy:What does the literature have to tell us?

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2022年第4期10卷 1454-1456页

作者： Jucier Gonçalves Júnior Samuel Katsuyuki Shinjo Division of Rheumatology São Paulo UniversitySão Paulo 01246-903Brazil

We presented a letter about a case of a 37-year-old Black female with a history of human immunodeficiency virus and an undetectable viral load.She was evaluated with weakness in the scapular(grade III)and pelvic girdles(grade II),elevation of creatine phosphokinase levels and muscle biopsy compatible with nemaline myopathy.She was treated with rituximab showing improvement of the condition.

关键词： Case report Human immunodeficiency virus Nemaline myopathy rituximab Rheumatology Therapy

rituximab combined with Bruton tyrosine kinase inhibitor to treat elderly diffuse large B-cell lymphoma patients: Two case reports

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Clinical Cases 2023年第29期11卷 7170-7178页

作者： Cang-Jian Zhang Min-Lei Zhao Department of Hematology Lishui Municipal Central HospitalLishui 323000Zhejiang ProvinceChina

BACKGROUND Diffuse large B-cell lymphoma(DLBCL)is a common aggressive non-Hodgkin's lymphoma(NHL),accounting for 30%-40%of adult NHLs.This report aims to explore the efficacy and safety of rituximab combined with Bruton tyrosine kinase inhibitors(BTKis)in the treatment of elderly patients with DLBCL.CASE SUMMARY The clinical data of two elderly patients with DLBCL who received rituximab combined with BTKi in our hospital were retrospectively analyzed,and the literature was reviewed.The patients were treated with chemotherapy using the R-miniCHOP regimen for two courses.Then,they received rituximab in combination with BTKi.CONCLUSION The treatment experience in these cases demonstrates the potential efficacy of rituximab combined with BTKi to treat elderly DLBCL patients,thus providing a new treatment strategy.

关键词： Diffuse large B-cell lymphoma rituximab Bruton tyrosine kinase inhibitors Elderly patients Case report

Fotemustine-based therapy in combination with rituximab as a first-line induction chemotherapy followed by WBRT for newly diagnosed primary central nervous system lymphoma: a prospective phase II trial

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2022年第7期19卷 1089-1099页

作者： Jingjing Wu Fenghua Gao Wenhua Wang Xudong Zhang Meng Dong Lei Zhang Xin Li Ling Li Zhenchang Sun Xinhua Wang Xiaorui Fu Linan Zhu Mengjie Ding Songtao Niu Zhaoming Li Yu Chang Feifei Nan Jiaqian Yan Hui Yu Xiaolong Wu Zhiyuan Zhou Jieming Zhang Mingzhi Zhang Cancer Research Institute Department of OncologyThe First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052HenanChina

Objective:This study aimed to evaluate the safety,efficacy,and feasibility of the rituximab,fotemustine,pemetrexed,and dexamethasone(R-FPD)regimen followed by whole-brain radiotherapy(WBRT)for patients with primary central nervous system lymphoma(PCNSL).Methods:A prospective,single-center phase II clinical trial was conducted.Patients with PCNSL newly diagnosed at the First Affiliated Hospital of Zhengzhou University between July 2018 and July 2020 were studied.The R-FPD regimen consisted of rituximab(375 mg/m2 i.***.on D0),fotemustine(100 mg/m2 i.***.on D1),pemetrexed(600 mg/m2 i.***.on D1),and dexamethasone(40 mg i.***.on D1-5).Patients 60 years or younger who showed a complete response(CR)were treated with 23.4 Gy of WBRT after the end of chemotherapy;those older than 60 years with CR were treated with a wait-and-see approach;and those who did not show CR after the 4th cycle of chemotherapy were given salvage WBRT 30 Gy+local tumor field irradiation up to 45 Gy,regardless of age.Results:A total of 30 patients were included.After 2 cycles,the objective response rate(ORR)was 96.5%(28/29,1 CR,27 PR,0 SD,and 1 PD).After 4 cycles,the ORR was 73.1%(19/26,11 CR,8 PR,4 SD,and 3 PD).After WBRT,the ORR was 90.9%(10/11,7 CR,3 PR,and 1 SD).The grade III and IV toxicity responses were mainly leukopenia(20.0%),thrombocytopenia(23.3%),and anemia(10.0%).Conclusions:Fotemustine-based therapy in combination with rituximab chemotherapy followed by WBRT can improve outcomes,providing ORR benefits and favorable tolerability in patients newly diagnosed with PCNSL.

关键词： rituximab primary central nervous system lymphoma pemetrexed fotemustine WBRT

Benefit of rituximab maintenance is associated with Follicular Lymphoma International Prognostic Index in patients with follicular lymphoma

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Blood Science 2023年第2期5卷 118-124页

作者： Ru Li Tingyu Wang Rui Lyv Yi Wang Ying Yu Yuting Yan Qi Sun Wenjie Xiong Wei Liu Weiwei Sui Wenyang Huang Huijun Wang Chengwen Li Jun Wang Dehui Zou Gang An Jianxiang Wang Lugui Qiu Shuhua Yi State Key Laboratory of Experimental Hematology National Clinical Research Center for Blood DiseasesHaihe Laboratory of Cell EcosystemInstitute of Hematology&Blood Diseases HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeTianjin 300020China Tianjin Institutes of Health Science Tianjin 301600China.

rituximab maintenance(RM)prolongs the progression-free survival(PFS)of responding patients with follicular lymphoma(FL),but the maintenance efficacy in different Follicular Lymphoma International Prognostic Index(FLIPI)risk group is still confusing.We performed a retrospective analysis of the effect of RM treatments in patients with FL responding to induction therapy based on their FLIPI risk assessment carried out prior to treatment.We identified 93 patients between 2013 and 2019 who received RM every 3 months for≥4 doses(RM group),and 60 patients who did not accept RM or received rituximab less than 4 doses(control group).After a median follow-up of 39 months,neither median overall survival(OS)nor PFS was reached for the entire population.The PFS was significantly prolonged in the RM group compared to the control group(median PFS NA vs 83.1 months,P=.00027).When the population was divided into the 3 FLIPI risk groups,the PFS differed significantly(4-year PFS rates,97.5%vs 88.8%vs 72.3%,P=.01)according to group.There was no significant difference in PFS for FLIPI low-risk patients with RM compared to the control group(4-year PFS rates,100%vs 93.8%,P=.23).However,the PFS of the RM group was significantly prolonged for FLIPI intermediate-risk(4-year PFS rates,100%vs 70.3%,P=.00077)and high-risk patients(4-year PFS rates,86.7%vs 57.1%,P=.023).These data suggest that standard RM significantly prolongs the PFS of patients assigned to intermediate-and high-risk FLIPI groups but not to low-risk FLIPI group,and pending larger-scale studies to validate.

关键词： Follicular lymphoma Follicular lymphoma international prognostic index Induction therapy Maintenance Progressionfree survival rituximab

Membranous nephropathy with systemic light-chain amyloidosis of remission after rituximab therapy:A case report

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

世界临床病例杂志 2023年第23期11卷 5538-5546页

作者： Jiao Zhang Xu Wang Gu-Ming Zou Jia-Yi Li Wen-Ge Li Beijing University of Chinese Medicine Beijing 100029China Department of Nephrology China-Japan Friendship HospitalBeijing 100029China

BACKGROUND About 70%-80%of patients with primary membranous nephropathy(MN)have phospholipase A2 receptor(PLA2R)in renal tissue.Systemic light-chain(AL)amyloidosis is the most common type of amyloidosis.MN complicated with amyloidosis is rare.CASE SUMMARY A 48-year-old Chinese male presented with nephrotic syndrome,positive serum PLA2R antibody,and positive serum and urine IgG-lambda type M-protein,with a normal ratio of serum-free light-chain level.The patient was diagnosed with MN accompanied by AL amyloidosis.He was treated with rituximab with glucocorticoids and CyBorD regimen of chemotherapy.After 21 mo of follow-up,the patient achieved complete remission regarding nephrotic syndrome without adverse effects of chemotherapy.CONCLUSION We report a case of PLA2R-related MN complicated with primary AL amyloidosis only with renal involvement and successfully treated with rituximab,glucocorticoids and chemotherapy.

关键词： Amyloidosis Membranous nephropathy Phospholipase A2 receptors rituximab Renal biopsy Case report

A multi-center,open-label,randomized,parallel-controlled phase II study comparing pharmacokinetic,pharmacodynamics and safety of ripertamab(SCT400)to rituximab(Mab Thera?)in patients with CD20-positive B-cell non-Hodgkin lymphoma

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Journal of Cancer Research 2022年第6期34卷 601-611页

作者： Xiaohong Han Mingzhi Zhang Huaqing Wang Qingyuan Zhang Wei Li Miaowang Hao Yuhuan Gao Jie Jin Hanyun Ren Yun Tang Xiaonan Hong Xiaoyan Ke Hang Su Lin Gui Jianmin Luo Liangzhi Xie Wenlin Gai Yuankai Shi Clinical Pharmacology Research Center Peking Union Medical College HospitalState Key Laboratory of Complex Severe and Rare DiseasesNMPA Key Laboratory for Clinical Research and Evaluation of DrugBeijing Key Laboratory of Clinical PK&PD Investigation for Innovative DrugsChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100730China Department of Oncology the First Affliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of Medical Oncology Tianjin People's HospitalTianjin 300121China Department of Medical Oncology Harbin Medical University Cancer HospitalHarbin 150081China Oncology Department of Cancer Center the First Hospital of jilin UniversityChangchun 130021China Department of Hematology Tangdu HospitalAir Force Medical UniversityXi'an 710038China Department of Hematology the Fourth Hospital of Hebei Medical UniversityShijiazhuang 050011China Department of Hematology the First Affliated Hospital of Zhejiang UniversityHangzhou 310003China Department of Hematology Peking University First HospitalBeijing 100034China Department of Hematology West China HospitalSichuan UniversityChengdu 610041China Department of Medical Oncology Fudan University Shanghai Cancer CenterShanghai 2032China Department of Hematology Peking University Third HospitalBeijing 100191China Department of Lymphoma the Fifth Medical Center of PLA General HospitalBeijing 100071China Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021China Department of Hematology the Second Hospital of Hebei Medical UniversityShijazhuang 050000China Beijing Engineering Research Center of Protein and Antibody Sinocelltech Ltd.Beijing 100176China

Objective:This multi-center,open-label,randomized,parallel-controlled phaseⅡstudy aimed to compare the pharmacokinetics(PK),pharmacodynamics(PD)and safety profile of ripertamab(SCT400),a recombinant antiCD20 monoclonal antibody,to rituximab(MabThera^(■))in patients with CD20-positive B-cell non-Hodgkin lymphoma(NHL).Methods:Patients with CD20-positive B-cell NHL who achieved complete remission or unconfirmed complete remission after standard treatment were randomly assigned at a 1:1 ratio to receive a single dose of ripertamab(375mg/m^(2))or rituximab(MabThera^(■),375 mg/m^(2)).PK was evaluated using area under the concentration-time curve(AUC)from time 0 to d 85(AUC_(0-85d)),AUC from time 0 to week 1(AUC0-1 w),AUC from time 0 to week 2(AUC_(0-2 w)),AUC from time 0 to week 3(AUC_(0-3 w)),AUC from time 0 to week 8(AUC_(0-8 w)),maximum serum concentration(C_(max)),terminal half-life(T_(1/2)),time to maximum serum concentration(T_(max))and clearance(CL).Bioequivalence was confirmed if the 90%confidence interval(90%CI)of the geometric mean ratio of ripertamab/rituximab was within the pre-defined bioequivalence range of 80.0%-125.0%.PD,immunogenicity,and safety were also evaluated.Results:From December 30,2014 to November 24,2015,a total of 84 patients were randomized(ripertamab,n=42;rituximab,n=42)and the PK analysis was performed on 76 patients(ripertamab,n=38;rituximab,n=38).The geometric mean ratios of ripertamab/rituximab for AUC_(0-85d),ATC_(0-inf),and Cmaxwere 96.1%(90%CI:87.6%-105.5%),95.9%(90%CI:86.5%-106.4%)and 97.4%(90%CI:91.6%-103.6%),respectively.All PK parameters met the pre-defined bioequivalence range of 80.0%-125.0%.For PD and safety evaluation,there was no statistical difference in peripheral CD 19-positive B-cell counts and CD20-positive B-cell counts at each visit,and no difference in the incidence of anti-drug antibodies was observed between the two groups.The incidences of treatment-emergent adverse events and treatment-related adverse events were also comparable between the two groups.Conclusion

关键词： Anti-CD20 monoclonal antibody non-Hodgkin lymphoma pharmacokinetics ripertamab rituximab safety

rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy： A Systematic Review and Meta-Analysis

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Chinese Medical Journal 2015年第3期128卷 378-383页

作者： Yuan-Rong Ren Yong-Dong Jin Zhi-Hui Zhang Li Li Ping Wu Department of Medical Oncology Sichuan Cancer Hospital and Institute Chengdu Sichuan 610000 China

Background： rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone （CHOP） significantly prolonged event-free survival in first-line chemotherapy for patients with diffuse large B-cell lymphoma （DLBCL）. But relapse and refractory DLBC L occur frequently. Although rituximab is effective, its role in salvage therapy after autologous transplant remains unclear. Maintenance therapy with rituximab in responding patients after first line chemotherapy may be a useful novel approach capable of eradicating minimal residual disease and to bring survival benefit. This systematic review and meta-analysis evaluated the effects of rituximab maintenance treatment and salvage therapy of patients with DLBCL. Methods： We performed a systematic review and meta-analysis of randomized controlled trials and compared rituximab maintenance or salvage therapy at relapse with observation. We searched the Cochrane Library, PubMed, EMBASE, conference proceedings, databases of ongoing trials, and references of published trials. Two reviewers independently assessed the quality of the trials and extracted data. Hazard ratios for time-to-event data were estimated and pooled. Results： Seven trials including 1470 DLBCL patients were included in this systematic review and recta-analysis. Patients treated with maintenance rituximab have better overall survival （OS） and event-tree survival （EFS） than patients in the observation arm, but there was no statistical significance. Patients who received rituximab salvage therapy for relapse or refractory DLBCL have statistically significantly better OS [HR of death = 0.72, 95% CI （0.55-0.94）, P - 0.02], progression-free survival （PFS） [HR - 0.61,95% CI（0.52-0.72）, P 〈 0.05], odds ratio （OR） [RR = 1.26, 95% CI（1.07-1,47）, P = 0.004] than patients in the observation arm. The rate of infection-related adverse events was higher with rituximab treatment [RR = 1.37, 95% CI = （ 1.14 - 1.65） P =0.001 ]. Conclusions： After first-line chemotherapy, the two rituximab-combined treatmen

关键词： Diffuse Large B Cell Lymphoma Meta-analysis： Review rituximab